[go: up one dir, main page]

ATE452204T1 - Screening-methoden unter verwendung eines strukturmodells von fih - Google Patents

Screening-methoden unter verwendung eines strukturmodells von fih

Info

Publication number
ATE452204T1
ATE452204T1 AT03758318T AT03758318T ATE452204T1 AT E452204 T1 ATE452204 T1 AT E452204T1 AT 03758318 T AT03758318 T AT 03758318T AT 03758318 T AT03758318 T AT 03758318T AT E452204 T1 ATE452204 T1 AT E452204T1
Authority
AT
Austria
Prior art keywords
fih
structural model
structural
screening methods
chemical entity
Prior art date
Application number
AT03758318T
Other languages
English (en)
Inventor
Peter John Ratcliffe
Christopher William Pugh
Christopher Joseph Schofield
Kirsty Sarah Hewitson
Jonathan Mark Elkins
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224102A external-priority patent/GB0224102D0/en
Priority claimed from GB0226598A external-priority patent/GB0226598D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE452204T1 publication Critical patent/ATE452204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Computing Systems (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03758318T 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih ATE452204T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224102A GB0224102D0 (en) 2002-10-16 2002-10-16 Inhibitors
GB0226598A GB0226598D0 (en) 2002-11-14 2002-11-14 Chemical inhibitors
PCT/GB2003/004492 WO2004035812A2 (en) 2002-10-16 2003-10-16 Asparaginyl hydroxylases and modulators thereof

Publications (1)

Publication Number Publication Date
ATE452204T1 true ATE452204T1 (de) 2010-01-15

Family

ID=32109245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03758318T ATE452204T1 (de) 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih

Country Status (11)

Country Link
US (1) US7778779B2 (de)
EP (2) EP2156830A1 (de)
JP (1) JP4465276B2 (de)
AT (1) ATE452204T1 (de)
AU (1) AU2003274330B2 (de)
CA (1) CA2502541A1 (de)
DE (1) DE60330587D1 (de)
ES (1) ES2337043T3 (de)
MX (1) MXPA05004033A (de)
PL (1) PL376770A1 (de)
WO (1) WO2004035812A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093411A2 (en) 2004-03-26 2005-10-06 Isis Innovation Limited Assays for identifying modulators of the hydroxylation of ankyrin repeat proteins by 2-oxoglutarate dependent oxigenase and methods of using the same
JP5007226B2 (ja) 2004-07-15 2012-08-22 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリンならびにノルエピネフリン、ドーパミン、およびセロトニンの再取り込みを遮断するためのその利用方法
GB0519605D0 (en) 2005-09-26 2005-11-02 Isis Innovation Assay
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
CN101506149B (zh) 2006-06-26 2012-11-14 华纳奇考特有限责任公司 脯氨酰羟化酶抑制剂及使用方法
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
KR20160017132A (ko) * 2008-12-19 2016-02-15 유럽피안 몰레큘러 바이올로지 래보러토리 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
PE20120373A1 (es) * 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
AU2010247735B2 (en) * 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
MX2012005275A (es) 2009-11-06 2012-06-19 Aerpio Therapeutics Inc Composiciones y metodos para tratar colitis.
KR101855471B1 (ko) 2009-12-04 2018-05-09 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
CA2837560C (en) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (de) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2014047447A2 (en) 2012-09-21 2014-03-27 Midwestern University Fto modulating compounds and methods of use
MY204336A (en) 2013-06-13 2024-08-23 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
KR102647879B1 (ko) 2015-04-01 2024-03-15 아케비아 테라퓨틱스 인코포레이티드 빈혈 치료용 조성물 및 방법
US10312653B2 (en) 2015-05-06 2019-06-04 Milwaukee Electric Tool Corporation Hydraulic tool
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
EA202090414A1 (ru) 2017-08-02 2020-05-28 Суновион Фармасьютикалз Инк. Соединения и их применение
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
JP7440989B2 (ja) 2018-05-09 2024-02-29 アケビア セラピューティクス インコーポレイテッド ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法
EP3938045A1 (de) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salze einer isochromanylverbindung und kristalline formen, verfahren zur herstellung, therapeutische verwendungen und pharmazeutische zusammensetzungen davon
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090301A2 (en) 2000-05-17 2001-11-29 Princeton University Crystallizing murg protein, methods of making and using models thereof for inhibition and stimulation via compounds
GB0017323D0 (en) 2000-07-15 2000-08-30 Univ St Andrews Enzyme
ES2282292T3 (es) 2000-09-22 2007-10-16 Wyeth Estructura cristalina de bace y usos de la misma.
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
AUPR773801A0 (en) * 2001-09-18 2001-10-11 Adelaide Research & Innovation Pty Ltd Asparagine hydroxylation of the cad domain of a hif protein

Also Published As

Publication number Publication date
US7778779B2 (en) 2010-08-17
AU2003274330B2 (en) 2009-06-04
ES2337043T3 (es) 2010-04-20
EP1554394B1 (de) 2009-12-16
MXPA05004033A (es) 2005-06-08
EP1554394A2 (de) 2005-07-20
WO2004035812A3 (en) 2004-08-19
US20070048728A1 (en) 2007-03-01
EP2156830A1 (de) 2010-02-24
CA2502541A1 (en) 2004-04-29
WO2004035812A2 (en) 2004-04-29
AU2003274330A1 (en) 2004-05-04
DE60330587D1 (de) 2010-01-28
JP4465276B2 (ja) 2010-05-19
JP2006504415A (ja) 2006-02-09
PL376770A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
DE60330587D1 (de) Screening-Methoden unter Verwendung eines Strukturmodells von FIH
Thien et al. Determination of bioavailable phosphorus in soil
Livingstone et al. The prediction of hypolimnetic oxygen profiles: a plea for a deductive approach
Donigan et al. Application Guide for Hydrological Simulation Program: FORTRAN(HSPF)
Wisshak et al. Ocean acidification accelerates reef bioerosion
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
DE69735127D1 (de) Enzymsensor
DE602005027646D1 (de) Verfahren zum Betrieb eines Navigationssystems zum Melden aktualisierter Teile einer geographischen Datenbank
DE60316517D1 (de) Verfahren und Vorrichtung zur Aufnahme von Störsignalen
DE60334365D1 (de) Leistungsverbesserung einer analytenüberwachungsvorrichtung
EA200501193A1 (ru) Улучшенный способ и система для выявления и/или прогнозирования биологических аномалий, например церебральных нарушений
ATE496141T1 (de) Verfahren und system zum analysieren von reaktionen unter verwendung eines informationssystems
DE69634782D1 (de) Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12
ATE507512T1 (de) Verfahren, computerprogramm mit programmcode- mitteln und computerprogramm-produkt zur analyse von einflussgrössen auf einen brennvorgang in einer brennkammer unter verwendung eines trainierbaren, statistischen modells
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE279769T1 (de) Vorrichtung und verfahren zum analysieren eines audiosignals hinsichtlich von rhythmusinformationen
ATE221657T1 (de) Entstörung durch rheumafaktoren
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
Lu et al. Multivariate calibration models based on the direct analysis of near-infrared single-beam spectra
Rohde et al. Applying early warning indicators to predict critical transitions in a lake undergoing multiple changes
DE3850346D1 (de) Verfahren zur Selbstdurchführung von Enzymkinetik.
ATE459077T1 (de) Verfahren und vorrichtung zur bestimmung der aufzeichnungsparameter von optischen platten
Rabouille et al. Annual and interannual variability of sedimentary recycling studied with a non-steady-state model: application to the North Atlantic Ocean (BENGAL site)
DE602005015627D1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties